Razak Pharmaceutical (DRZK) Has Risen About 176% Since Its June 15 Reopening, Closing Each Session Bid-Locked; Behind the Run, a Jump in Quarterly Profit and a P/E Below the Sector Average

A pharma stock few were watching, Razak, rose one hundred seventy six percent from June fifteen to August nineteen. Razak was halted for about four months and missed the market's climb, then it reopened. From June fifteen, when it was about fourteen hundred rials, it rose almost every session. On Wednesday August nineteen it closed at three thousand nine hundred eighty rials on a buy queue. That day volume ran near five times the twenty session average, and retail investors were buyers. From about fourteen hundred rials to nearly four thousand, a gain of one hundred seventy six percent. The main driver was the three month statement, showing net profit more than fifteen times last year. Revenue grew ninety two percent and return on equity is about thirty three percent. Even so, Razak's price to earnings is about eight point eight, below the sector's thirteen. On one side, jumping profit and value; on the other, catch up from the halt and unaudited figures. The lesson is clear: one fundamental number showed up in price through buy queues after a halt. Read the full story on Sahmino dot com; do you think this rally continues or a correction is due?